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ABSTRACT The human pre-MRNA splicing factors SF2
and SC35 have similar dectrophoretic mobil , and both of
them contain an N-terminal ribonucleoprotein (RNP)-type
RNA-recognition motif and a C-terminal ginine/serine-rich
domain. However, the two proteins are encoded by different
genes and display only 31% amino acid sequence identity. Here
we report a systematic comp of the splicing activities of
recombinant SF2 and SC35. We find that either protein can
reconsitute the splicing activity of S100 extracts and of SC35-
immunodepleted nuclear extracts. Previous studies revealed
that SF2 influences alternative 5' splice site in vilro, by
favoring proximal over distl 5' splice sites, and that the Al
protein of heterogeneous nuclear RNP counterats this effect.
We now show that SC35 has a similar effect on compeig 5'
spike sites a is also agonized by A prein. In adio,
we report that both SF2 and SC35 also favor the proximal ste
in a pre-mRNA coting duplIcated 3' splice sites, but this
effect is not modulated by Al. We conclude that SF2 and SC35
are distnct splicn factors, but they display
splicing activities in vitro.
Nuclear pre-mRNA splicing takes place in spliceosomes,
high molecular weight complexes containing small nuclear
ribonucleoprotein (snRNP) particles and non-snRNP protein
splicing factors (1). Our laboratories have identified and
characterized two distinct non-snRNP splicing factors des-
ignated SF2 (splicing factor 2) (2-4) and SC35 (spliceosome
component of 35 kDa) (5, 6). SF2 is also known as ASF or
ASF-1 (alternative splicing factor) (7, 8), whereas SC35 has
also been termed PR264 (9). In separate studies, SF2/ASF (3,
7) and SC35 (5, 10, 11) were shown to be required for the first
step of splicing and for the assembly ofthe earliest detectable
ATP-dependent prespliceosome complex (A complex). SF2
was originally identified by its ability to complement splicing-
deficient HeLa cell S100 extracts (2), and SC35 by its ability
to complement nuclear extracts immunodepleted with an
anti-SC35 monoclonal antibody (mAb) raised against par-
tially purified mammalian spliceosomes (5, 10). In addition,
SF2 was shown to activate preferentially the proximal 5'
splice site in pre-mRNAs containing two or more alternative
5' splice sites (4, 7, 12), a reaction that is specifically
counteracted by the Al protein of heterogeneous nuclear
RNP (hnRNP) particles (13). A systematic comparison of the
activities ofSF2 and SC35 was previously not possible, since
homogeneous preparations of each protein were not avail-
able.
SF2 and SC35 are phosphoproteins that migrate in SDS/
polyacrylamide gels as doublets, with very similar apparent
molecular masses (33-35 kDa), and the two proteins copurify
through multiple chromatographic steps (3, 6, 10). These
observations, in conjunction with the requirement of both
factors for complex A assembly, suggested that they may
actually correspond to the same protein. The slight differ-
ences in apparent molecular mass could be due to differences
in posttranslational modifications. However, comparison of
the nucleotide sequences of SF2/ASF-1 (8, 14) and SC35/
PR264 (6, 9) cDNA clones revealed that they encode highly
related but distinct polypeptides. SF2 is a 248-amino acid (aa)
protein of 27,744 Da, whereas SC35 is a 221-aa protein of
25,575 Da, not taking into account posttranslational modifi-
cations. Both SF2 and SC35 contain a RNP-type RNA-
recognition motif(RRM) (15, 16) and C-terminal arginine and
serine repeats (RS domain), but they display only 31%
sequence identity. The two cDNAs encode proteins with
splicing activities indistinguishable from those purified from
HeLa cell nuclear extracts. Recombinant SF2 produced in
bacteria complemented S100 extracts and influenced 5' splice
site selection in vitro (8, 14), whereas recombinant SC35
produced in a baculovirus system could complement anti-
SC35 immunodepleted extracts (6).
Recently, both proteins were shown to be members of the
SR family of phosphoproteins (17-19). Proteins in this family
are recognized by mAb 104, which is specific for a shared
phospho-epitope; copurify in a highly selective two-step
purification procedure; and contain an N-terminal RRM and
a C-terminal RS domain (19). The SR family consists of at
least five members of apparent molecular mass 20, 30, 40, 55,
and 75 kDa, which are highly conserved between Drosophila
and man. The 55-kDa polypeptide, SRp55 (17), isolated from
a Drosophila cell line, can complement HeLa cell S100
extracts for splicing and causes the preferential selection of
proximal 5' splice sites (18). Moreover, each of the 30-, 40-,
55-, and 70-kDa SRpolypeptides from calfthymus, recovered
individually from SDS/polyacrylamide gels, can complement
HeLa cell S100 extracts for splicing (19). Partial amino acid
sequence analysis ofthe human 30-kDa species revealed both
SF2 and SC35 polypeptides, respectively designated SRp3Oa
and SRp30b (19). Thus, it was not clear whether the in vitro
splicing activity of the purified 30-kDa protein was due to the
presence of SF2, SC35, or both.
Here we compare the splicing activities of recombinant
SF2 and SC35. We find that the two factors have indistin-
guishable activities in vitro. Both factors can complement
S100 extracts for splicing, and SF2 can substitute for SC35 in
complementing extracts immunodepleted with the anti-SC35
mAb. In addition, both SF2 and SC35 favor proximal over
distal 5' splice sites, and this proximal splice site selection
activity of both proteins is counteracted by hnRNP Al.
Finally, both SF2 and SC35 can also influence 3' splice site
selection in apre-mRNA containing competing 3' splice sites.
This latter activity is not affected by hnRNP Al.
Abbreviations: RNP, ribonucleoprotein; hnRNP, heterogeneous nu-
clear RNP; snRNP, small nuclear RNP; mAb, monoclonal antibody;
RRM, RNA-recognition motif; aa, amino acid(s).
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MATERIALS AND METHODS
Pre-mRNA Substrates. Wild-type ,8-globin plasmid tem-
plate (H#lA6) and derivatives containing a 5' splice site
duplication (5'D16X) or a 3' splice site duplication (3'D115)
were described previously (20, 21). Capped, 32P-labeled
RNAs were prepared from BamHI-linearized templates by in
vitro transcription with SP6 RNA polymerase (2).
Recombinant Proteins. SF2 was expressed in Escherichia
coli and purified (14). SC35 was expressed in Sf9 cells in a
baculovirus vector and purified (6). The hnRNP Al protein
was expressed in E. coli and purified (13). The concentrations
of purified recombinant proteins used were approximately
0.13 mg/ml (SC35), 0.06 mg/ml (SF2), and 0.2 mg/ml
(hnRNP Al). Some experiments employed purified HeLa cell
SF2 (0.13 mg/ml) that was shown to be devoid ofSC35 (A.M.
and A.R.K., unpublished data).
Splci Reactions. HeLa cell nuclear and S100 extracts
were prepared as described (2). SC35-depleted nuclear ex-
tract was prepared by using anti-SC35 mAb bound to protein
G-agarose (6). Standard 25-pul reaction mixtures (20, 22)
contained the amounts of nuclear extract, S100 extract, and
recombinant proteins indicated in each figure legend. All
extracts and fractions were dialyzed in modified bufferD (2).
All reactions were supplemented with the same buffer, when
necessary, to bring the total amount of buffer to 15 ul.
RESULTS
SF2 and SC35 Complement the Same Splig-Deficient
Extracs. Recombinant SF2 and human or bovine 30-kDa SR
protein (SRp30) isolated from preparative SDS/polyacryl-
amide gels can complement S100 extracts for splicing (4, 18,
19). However, gel-purified SRp30 contains both SF2 and
SC35 (19). To determine whether SC35 alone can comple-
ment the S100 extract, we compared the splicing activities of
recombinant SF2 and SC35. Comparable levels of ,-globin
pre-mRNA splicing were observed when equivalent amounts
of SF2 and SC35 were used to complement HeLa cell S100
extract (Fig. 1A, lanes 2 and 4; Fig. 1B, lanes 3 and 4). Thus,
the S100 extract is deficient in both SF2 and SC35, and either
protein can reconstitute splicing activity.
We next tested whether recombinant SF2 could comple-
ment SC35-depleted HeLa cell nuclear extract for splicing.
SF2 efficiently complemented the SC35-depleted nuclear
extract (Fig. 2). This particular preparation of SF2 was less
active than SC35 in both complementation assays (lanes 4
and 6), but this is unlikely to reflect a biologically scant
difference, since E. coli-expressed SF2 was subjected to a
denaturation-renaturation protocol and is sensitive to re-
peated freezing and thawing. Since SF2 and SC35 are func-
tionally redundant in vitro, and SC35-depleted extracts are
not active, it appears that SF2 and SC35 may be codepleted
by the anti-SC35 mAb. Indeed, immunoblot analysis of
anti-SC35- and control mAb-immunodepleted nuclear ex-
tracts indicated that anti-SC35 mAb immunodepletion re-
sulted in the partial but selective depletion of not only SC35
but also SF2 and SRp7S (data not shown). Coimmunodeple-
tion appears to be due, at least in part, to crossreactivity of
the anti-SC35 mAb with SF2, which can be observed by
immunoblotting of recombinant SF2 expressed in baculovi-
rus, but not of SF2 expressed in bacteria (data not shown),
consistent with the finding that this mAb recognizes a phos-
pho-epitope (X.-D.F. and T.M., unpublished data). In addi-
tion, coimmunodepletion may reflect the existence of the SR
proteins in a common high molecular weight complex in
nuclear extracts (see Discussion).
SF2 and SC35 Stim te Pro 5' Splice Sites-i Vitro.
Human SF2 and Drosophila SRpS5 can modulate 5' splice
site selection in vitro with alternatively spliced pre-mRNAs,
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FIG. 1. Recombinant SF2 and SC35 complement HeLa cell S100
extracts. (A) Purified recombinant SF2 and SC35. SF2 was produced
in E. coli and SC35 was produced by baculovirus. The indicated
amounts of SF2 and SC35 were analyzed by SDS/PAGE and
Coomassie blue R250 staining. The slower migration of SC35 is
caused by phosphorylation in the 519 insect cells. Lanes M, size
markers. (B) Splicing activity ofrecombinant SF2 and SC3S. Human
P-globin pre-mRNA was incubated under splicing conditions in
HeLa nuclear extract (NE, 4 ,p; lane 1) or in S100 extract alone (7
Al) or supplemented with 3 ,l of recombinant SC35 (ane 3), 6 i4 of
recombinant SF2 (lane 4), or 6 p4 of recombinant bicoid protein as a
negative control (lane 5). Positions of pre-mRNA and mRNA are
indicated. Lane M, size markers. nt, Nucleotides.
so that proximal 5' splice sites are favored at high SF2 or
SRp55 concentrations (4, 7, 8, 12, 14, 18). To investigate
whether recombinant SC35 has a similar effect on 5' splice
site selection in vitro, we analyzed the splicing pattern of a
model pre-mRNA containing a duplicated 5' splice site
(5'D16X) (21) in nuclear extract and in S100 extract supple-
mented with recombinant SC35. In nuclear extract the distal
5' splice site of 5'D16X pre-mRNA was preferentially used
(Fig. 3, lane 1). However, with increasing amounts of SC35
the proximal 5' splice site was selected with increasing
efficiency, while use of the distal 5' splice site remained
approximately the same (lanes 2-4). When the 5'D16X pre-
mRNA was spliced in S100 extract plus SC35, selection ofthe
distal 5' splice site became very inefficient (lanes 6and 7), and
a complete switch to the proximal 5' splice site was obtained
as the concentration of SC35 increased (lane 8). An essen-
tially identical pattern of 5' splice site selection was previ-
ously reported with this substrate and purified HeLa cell or
recombinant SF2 (refs. 4 and 14; see also lane 9). As
expected, no splicing activity or 5' splice site switching was
observed when recombinant bicoid protein was added (lane
10 and data not shown). We conclude that SC35 and SF2 are
indistinguishable in the 5' splice site selection assay.
The S' Splae Site &N _ AcvItes of SF2 and SC35 Are
Counterced by nN Al. The 5' splice site selection
patterns of several alternatively spliced pre-mRNAs are
different in nuclear extracts, or in SF2-supplemented nuclear
extracts, from those observed in S100 extracts comple-
mented with SF2 (refs. 4 and 13; see also Fig. 3). Recently,
this difference was shown to be due to the high concentration
of hnRNP Al in nuclear extract, which counteracts the SF2
effect on alternative 5' splice site selection in vitro and
thereby preferentially stimulates distal 5' splice sites (13). A
Biochemistry: Fu et aL
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FIG. 2. Recombinant SF2 and SC35 complement HeLa nuclear
extract immunodepleted with the anti-SC35 mAb. Nuclear extract
(NE) was depleted with either an isotype-matched control mAb (lane
1) or anti-SC35 mAb (lanes 2-4). The SC35-depleted nuclear extract
(7.5 Il) was complemented with 3 Al of SC35 (lane 3) or with 6 ILI of
SF2 (lane 4). Complementation of the S100 extract (7 Al) with SF2 (6
IL; lane 6) and SC35 (3 ILI; lane 7) was included for comparison of
their relative activities in these two complementation systems.
Substrate was wild-type human P-globin pre-mRNA.
similar activity, termed DSF, was partially purified from
HeLa cells (23), but it is not known if it is identical to hnRNP
Al. To determine whether hnRNP Al can oppose SC35-
mediated 5' splice site selection in vitro, we carried out
similar experiments. We found that increasing amounts of
hnRNP Al in S100 extracts complemented with a fixed
amount of SC35 resulted in a switch from the proximal to the
distal 5' splice site (Fig. 4, lanes 2-7). When a fixed amount
of hnRNP Al was added to the S100 extract, increasing
amounts of SC35 had an opposite effect, resulting in an
increase in the use of the proximal 5' splice site (lanes 8-12).
Thus, hnRNP Al has similar antagonistic effects on SC35 and
SF2 in 5' splice site selection in vitro.
SF2 and SC35 Influence 3' SpIce Site Selection in Vitro. SF2,
SC35, and SRp55 can strongly influence 5' splice site selec-
tion in vitro (see above), whereas only a limited effect on 3'
splice site selection by SF2 was previously reported (4).
Since SC35 appears to be one of the splicing factors that
mediate U1 and U2 interactions at the 3' splice site (11), it is
possible that SC35 and other SR proteins can also affect 3'
splice site choice in vitro. To test this possibility, we used a
pre-mRNA containing duplicated 3' splice sites (3'D15, ref.
21; Fig. 5) and examined its splicing patterns in dilute nuclear
extract in the absence, or in the presence of variable
amounts, of SC35 or SF2. SC35 had a selective, dose-
dependent effect on 3' splice site selection of the 3'Dll5
pre-mRNA by promoting the use of its proximal site (Fig. 5,
lanes 1-3). A virtually identical concentration-dependent
effect on 3' splice site selection was mediated by SF2 (lanes
4 and 5). We conclude that both SC35 and SF2 influence 3'
as well as 5' splice site selection in vitro. In contrast to the 5'
splice site switching activity, the preferential activation ofthe
proximal 3' splice site of 3'D115 by SF2 and SC35 was not
counteracted by hnRNP Al (data not shown).
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FIG. 3. Recombinant SC35 modulates 5' splice site selection in
vitro. Recombinant SC35 was added in increasing amounts to 4 Aul of
nuclear extract (NE, lanes 1-4) or to 7 jAl of S100 extract (lanes 5-8)
programmed with the 5'D16X pre-mRNA, which contains duplicated
5' splice sites. Lanes 1 and 5, no addition; lanes 2 and 6, 1.5 Ill; lanes
3 and 7, 3 u1; lanes 4 and 8, 6 ,41. S100 was also complemented with
6 1IL of SF2 (lane 9) or with 6 jul of bicoid (lane 10) as positive and
negative controls, respectively. Positions of the mRNA products
generated by selection of proximal (Prox.) or distal (Dist.) 5' splice
sites are indicated. Lane M, size markers as in Fig. 1B.
DISCUSSION
We report the results of a systematic comparison of the in
vitro splicing activities of recombinant SF2 and SC35. These
two splicing factors were initially identified by very different
approaches but appeared to be remarkably similar in their
physical properties, biochemical fractionation, and require-
ment for spliceosome assembly. However, the two activities
were later shown to represent homologous (31% amino acid
sequence identity) but distinct polypeptides. Our analysis of
the recombinant proteins did not reveal any differences in
their activities in vitro. Both proteins efficiently complement
-HeLa cell S100 extracts, as well as nuclear extracts immu-
nodepleted with anti-SC35, and influence 5' and 3' splice site
selection in pre-mRNAs containing competing splice sites.
Thus, the in vivo function of the two proteins remains
unknown. The two proteins could be entirely redundant in
their activities in vivo, they could preferentially associate
with particular pre-mRNAs or splice sites, or they could be
expressed at different levels in different cell types.
Other members of the SR family of splicing factors can
complement S100 extracts (18, 19), and Drosophila SRp55
can influence 5' splice site selection in a human in vitro
system (18). The activities of the remaining SR proteins in
alternative 5' or 3' splice site selection in vitro have not been
reported. Although it is possible that a careful analysis of the
in vitro activities of recombinant SR proteins may reveal
some differences, functional differences may be discernible
only in vivo. The conservation ofthe entire set ofSR proteins
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FIG. 4. hnRNP Al counteracts the effect ofSC35 on 5' splice site
selection. S100 extract (6 I1) was complemented with 3 Al of
recombinant SC35 (lanes 2-7) and increasing amounts of recombi-
nant hnRNP Al (lane 2, no addition; lane 3, 0.5 I; lane 4, 1 I1; lane
5, 2 Al; lane 6, 4 Al; lane 7, 6 I1) or with 3 ,l ofhnRNP Al (lanes 8-12)
and increasing amounts of SC35 (lane 8, no addition; lane 9, 0.751l;
lane 10, 1.5 Al; lane 11, 3 Al; lane 12, 6 Al). Nuclear extract (lane 1,
8 1l) was included as a control. Substrate was 5'D16X pre-mRNA.
Positions of the mRNA products generated by selection of proximal
or distal 5' splice sites are indicated. Lane M, size markers (Fig. 18).
between Drosophila and man strongly suggests that the
proteins are not entirely redundant in vivo. Thus, although
the functions that are currently measured in vitro tolerate
substantial size and sequence divergence-e.g., between
human SF2 (248 aa) and human SC35 (221 aa) (31% identi-
ty)-distinct members of the family have been remarkably
conserved phylogenetically. For example, human SF2
(SRp3Oa) and Drosophila SRpS5 (350 aa) exhibit 50%6 identity
(18) even though they are not true homologues: partial amino
acid sequence of purified proteins showed that there is a
homologue of SRp55 in vertebrates and of SRp3Oa in Dro-
sophila, each conserved in size and sequence (19). Homol-
ogous members of the family exhibit even greater conserva-
tion: human and avian SC35/PR264 (SRp3Ob; 98% identity)
(9), mouse X16 and human SRp2O (164 aa; 100%o identity) (19,
24), human SRp20 and Drosophila rbpl (135 aa, Y.-J. Kim
and B. S. Baker, personal communication; 63% identity).
The possibility that at least some members of the SR family
may function in a tissue-specific or developmentally regu-
lated manner is suggested by the observation that expression
of mouse X16 (SRp2O) mRNA is high in thymus, spleen, and
testes but low or undetectable in liver, kidney, brain, and
heart (24). Similarly, variable levels of SC35/PR264 mRNAs
are expressed in different cell lines and stages ofdevelopment
(6, 9), and the abundance of SF2 protein varies considerably
in different adult rat tissues (A.R.K., unpublished data).
A number of observations suggest that SF2, SC35, and
other SR proteins may be associated with each other in the
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FIG. 5. SF2 and SC35 modulate 3' splice site selection in vitro.
Splicing of the 3'D115 pre-mRNA, which contains duplicated 3'
splice sites, was carried out in nuclear extract (NE, 3 j1) supple-
mented with recombinant SC35 (lane 1, no addition; lane 2, 2 I1; lane
3, 8u14) or purified HeLa cell SF2 (lane 4, 2u14; lane 5, 8 Al). Positions
of the mRNA products generated by selection of proximal or distal
3' splice sites are indicated.
cell. (i) SR proteins colocalize in discrete nuclear structures
along with other spliceosome components such as snRNPs
(25). This was demonstrated by immunofluorescence stain-
ing, confocal laser scanning, and/or immuno-electron mi-
croscopy with the mAbs anti-SC35 (5, 10), anti-SF2 (D.
Spector and A.R.K., unpublished data), and 104, which
recognizes all SR family members (26). (ii) HeLa cell S100
extracts appear to be deficient in all SR family proteins, but
contain all other essential spliceosomal components. Thus,
as discussed above, SF2, SC35, and all other SR family
proteins thus far tested can reconstitute the splicing activity
of S100 extracts. The spliceosomal components present in
these "cytoplasmic" S100 extracts leak out of the nucleus
when the cells are lysed in a hypotonic buffer (2). It is
therefore possible that the absence of SR proteins from S100
extracts is due to association of these proteins to form a
protein or RNP complex too large to leak out of the nucleus
at low salt concentrations (3). Alternatively, the SR proteins
may be pelleted during the standard ultracentrifugation ofthe
S100 extract in the presence of Mg2+ (19). We favor the
former explanation because omission or chelation of Mg2+
during the ultracentrifugation step does not yield an S100
extract that is active in splicing in the absence of added SR
proteins, and because a similar spin in the presence of Mg2+
does not inactivate a nuclear extract (unpublished data). (iii)
SF2 activity is present in rapidly sedimenting endogenous
RNP complexes in nuclear extracts and can be released from
these complexes by incubation in the presence of ATP (27).
(iv) Nuclear extracts that are immunodepleted with the
Biochemistry: Fu et A
Proc. Nat!. Acad. Sci. USA 89 (1992)
anti-SC35 mAb are also deficient in other SR family mem-
bers. The anti-SC35 mAb shows variable crossreactivity with
denatured SF2 and other SR proteins by immunoblot analy-
sis, depending on their phosphorylation states, demonstrat-
ing the existence of a conserved epitope. However, code-
pletion ofthe native SR proteins with the anti-SC35 mAb may
be due to the association of all SR proteins to form a high
molecular weight complex in nuclear extracts.
Both S100 extracts and SC35-immunodepleted extracts
contain limiting but detectable amounts ofSF2 and SC35, and
probably other SR proteins. If these proteins are part of a
common protein or RNP complex, it is possible that addition
of any of the SR proteins drives assembly of the complex so
that it is no longer limiting for activity. If this is the case, each
of the SR proteins may be necessary for activity, and the
apparent redundancy may be a consequence of incomplete
depletion. When recombinant SF2 and SC35 are added
together in any of the assays described here, their effects are
only additive (data not shown), suggesting that these two
proteins are redundant or that other SR proteins have become
limiting.
SF2 and SC35 are general splicing factors and are nonspe-
cific RNA-binding proteins. In addition, SF2 was previously
shown to have a dramatic effect on 5' splice site selection
with a variety of pre-mRNAs containing alternative 5' splice
sites and a common 3' splice site. Here we show that SC35
has the same effect on 5' splice site selection as SF2 and,
further, that the two proteins also have similar effects on 3'
splice site selection. The more limited effect of SF2 on 3'
splice site selection reported previously (4) can be attributed
to a suboptimal ratio of nuclear extract and SF2. Just as
hnRNP Al antagonizes the proximal 5' splice site selection
activity ofSF2 and SC35, a pair of antagonistic activities, SF6
and SF7, determine the selection of competing 3' splice sites
in vitro (A.M. and A.R.K., unpublished work). Whereas SF6
activity, which favors proximal 3' splice sites, is present in
SF2 and SC35, an excess of SF7 causes the selection ofdistal
3' splice sites. To minimize SF7 activity, less nuclear extract
was employed in the present study. An activity that stimu-
lates use of a proximal duplicated 3' splice site in a 8-crys-
tallin model pre-mRNA has been partially purified (N.
Kataoka and Y. Shimura, personal communication) and may
prove to be one of the SR proteins.
The hnRNP Al protein counteracts the effects of both SF2
and SC35 on 5' splice site selection in vitro, but the mecha-
nism of this effect is not understood. The effect is specific,
since hnRNP Al does not inhibit general splicing, which
requires SR proteins, and actually slightly enhances splicing
(13). Moreover, no analogous effects of hnRNP Al at 3'
splice sites were observed with the substrates tested so far
(ref. 13; this study). One possibility is that hnRNP Al and
splicing factors compete for access to the 5' splice sites (13).
The equilibrium binding of hnRNP Al to single-stranded
polyaucleotides is cooperative and shows limited base spec-
ificity (28). In vitro reconstitution studies with hnRNP core
proteins also show a lack of sequence specificity (29). How-
ever, the contacts ofhnRNP Al with pre-mRNA are sensitive
to the presence of additional factors in nuclear extracts (30),
and specific binding ofhRNP Al to the 5' (D. Stolow and S.
Bernet, personal communication) and 3' (31) splice sites
under splicing conditions has been reported. The dfferences
in the effects of hnRNP Al on 5' and 3' splice site selection
by SF2 or SC35 may be explained if hnRNP Al has a higher
affinity for 5' splice sites than for 3' splice sites. Once SF7 is
idenified, it should be possible to determine how all these
competing factors influence each other upon binding to
pre.mRNA.
Additional pre-mRNAs containing alternative 3' splice
sites should be studied to determine whether the selective
effects of SF2 and SC35 are general, and whether the
proximal site is always favored, as in the case of alternative
5' splice sites. The combined stimulation of proximal 5' and
3' splice sites by SF2 and SC35 may serve to prevent
inappropriate exon skipping (ref. 4; A.M., D. Helfman, and
A.R.K., unpublished work). In addition, in vivo modulation
of the levels or activities of these and other SR proteins, as
well as of hnRNP Al and SF7, may regulate the expression
of some of the many genes that are alteratively spliced in a
tissue-specific or developmentally contrlled, manner. Simi-
lar studies with other purified general _ should
show whether the concentration-dependent poff effects on
alternative splice site selection are a unique property ofthese
and/or other SR proteins.
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